01 21Synagis
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2017 Revenue in Millions : 738
2016 Revenue in Millions : 730
Growth (%) : 1
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2016 Revenue in Millions : 730
2015 Revenue in Millions : 740
Growth (%) : -1
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2015 Revenue in Millions : 835
2014 Revenue in Millions : 740
Growth (%) : -11%
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2018 Revenue in Millions : 726
2017 Revenue in Millions : 738
Growth (%) : -2%
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2019 Revenue in Millions : 718
2018 Revenue in Millions : 726
Growth (%) : -1
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2014 Revenue in Millions : 1.00%
2013 Revenue in Millions :
Growth (%) :
Main Therapeutic Indication : Immunology
Currency : USD
2019 Revenue in Millions : 259
2018 Revenue in Millions : 0
Growth (%) : N/A
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2020 Revenue in Millions : 372
2019 Revenue in Millions : 358
Growth (%) : 4
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2021 Revenue in Millions : 410
2020 Revenue in Millions : 372
Growth (%) : 10
Main Therapeutic Indication : Immunology
Currency : USD
2020 Revenue in Millions : 327
2019 Revenue in Millions : 311
Growth (%) : 5
LOOKING FOR A SUPPLIER?